53,706 Shares in Exelixis, Inc. (NASDAQ:EXEL) Acquired by Massar Capital Management LP

Massar Capital Management LP purchased a new stake in Exelixis, Inc. (NASDAQ:EXEL - Free Report) during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm purchased 53,706 shares of the biotechnology company's stock, valued at approximately $1,788,000. Exelixis makes up about 2.0% of Massar Capital Management LP's portfolio, making the stock its 18th biggest holding.

Other large investors have also added to or reduced their stakes in the company. USA Financial Formulas purchased a new stake in Exelixis in the 4th quarter valued at about $32,000. Principal Securities Inc. increased its stake in Exelixis by 62.8% in the 4th quarter. Principal Securities Inc. now owns 967 shares of the biotechnology company's stock valued at $32,000 after buying an additional 373 shares during the last quarter. Kestra Investment Management LLC purchased a new stake in Exelixis in the 4th quarter valued at about $39,000. UMB Bank n.a. increased its stake in Exelixis by 68.4% in the 4th quarter. UMB Bank n.a. now owns 1,361 shares of the biotechnology company's stock valued at $45,000 after buying an additional 553 shares during the last quarter. Finally, Crowley Wealth Management Inc. purchased a new stake in Exelixis in the 4th quarter valued at about $50,000. Institutional investors own 85.27% of the company's stock.

Exelixis Trading Up 0.6 %

NASDAQ EXEL traded up $0.22 on Friday, hitting $37.43. The company's stock had a trading volume of 1,709,889 shares, compared to its average volume of 2,182,134. Exelixis, Inc. has a 52-week low of $20.14 and a 52-week high of $40.02. The company's 50-day simple moving average is $36.68 and its 200 day simple moving average is $34.73. The firm has a market cap of $10.32 billion, a P/E ratio of 21.15, a PEG ratio of 1.13 and a beta of 0.57.

Exelixis (NASDAQ:EXEL - Get Free Report) last released its earnings results on Tuesday, February 11th. The biotechnology company reported $0.48 EPS for the quarter, missing analysts' consensus estimates of $0.51 by ($0.03). Exelixis had a net margin of 24.04% and a return on equity of 23.52%. On average, research analysts forecast that Exelixis, Inc. will post 2.04 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several brokerages have recently issued reports on EXEL. JMP Securities restated a "market outperform" rating and set a $41.00 price target on shares of Exelixis in a research note on Thursday, April 17th. UBS Group reaffirmed an "underperform" rating on shares of Exelixis in a report on Thursday, April 17th. Morgan Stanley raised shares of Exelixis from an "equal weight" rating to an "overweight" rating and raised their price objective for the stock from $30.00 to $40.00 in a report on Monday, January 27th. Oppenheimer downgraded shares of Exelixis from an "outperform" rating to a "market perform" rating and cut their price objective for the stock from $41.00 to $33.00 in a report on Friday, January 24th. Finally, Piper Sandler raised their price objective on shares of Exelixis from $37.00 to $38.00 and gave the stock an "overweight" rating in a report on Wednesday, February 12th. Two research analysts have rated the stock with a sell rating, six have assigned a hold rating, twelve have given a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and a consensus target price of $37.59.

Insider Buying and Selling at Exelixis

In related news, CFO Christopher J. Senner sold 29,314 shares of the stock in a transaction on Monday, February 24th. The stock was sold at an average price of $36.14, for a total transaction of $1,059,407.96. Following the sale, the chief financial officer now directly owns 779,607 shares of the company's stock, valued at $28,174,996.98. This trade represents a 3.62 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, EVP Patrick J. Haley sold 10,000 shares of the business's stock in a transaction dated Monday, March 3rd. The stock was sold at an average price of $38.80, for a total value of $388,000.00. Following the completion of the transaction, the executive vice president now directly owns 341,028 shares of the company's stock, valued at approximately $13,231,886.40. This trade represents a 2.85 % decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 140,343 shares of company stock worth $5,177,234. 2.85% of the stock is owned by insiders.

Exelixis Profile

Exelixis, Inc, an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer.